ERBB2 and cancer: Multivariate Cox regression analysis showed HER2 amplification was an independent risk factor for worse DFS, tumors with HER2 amplification were associated with a 2.53-fold increase in risk of cancer recurrence (HR = 2.53, 95% CI [1.21–5.30], P = 0.014) (Table 3).